-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Dapirolizumab Pegol in Systemic Lupus Erythematosus
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Dapirolizumab Pegol in Systemic Lupus Erythematosus Drug Details:Dapirolizumab pegol (CDP-7657) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cetuximab Biosimilar in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Cetuximab Biosimilar in Ovarian Cancer Drug Details: Cetuximab biosimilar (CDP-1) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Olokizumab in Rheumatoid Arthritis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Olokizumab in Rheumatoid Arthritis Drug Details: Olokizumab (Artlegia) is a humanized monoclonal antibody. It is formulated...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Romosozumab in Osteoporosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Romosozumab in OsteoporosisDrug Details: Romosozumab (Evenity) is a humanized monoclonal antibody. It is formulated as solution...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Romosozumab in Osteogenesis Imperfecta
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Romosozumab in Osteogenesis ImperfectaDrug Details: Romosozumab (Evenity) is a humanized monoclonal antibody. It is formulated as...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NLG-207 in Small-Cell Lung Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NLG-207 in Small-Cell Lung Cancer Drug Details: NLG-207 (CRLX-101) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NLG-207 in Epithelial Ovarian Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NLG-207 in Epithelial Ovarian Cancer Drug Details: NLG-207 (CRLX-101) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NLG-207 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NLG-207 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Drug Details: NLG-207 (CRLX-101) is under...
-
Product Insights
![]()
CDP – Lake House Development – California
Equip yourself with the essential tools needed to make informed and profitable decisions with our CDP - Lake House Development - California report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into the CDP...
-
Product Insights
![]()
CDP – Piazza Verdi Redevelopment – Latium
Equip yourself with the essential tools needed to make informed and profitable decisions with our CDP - Piazza Verdi Redevelopment - Latium report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into the CDP...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.